Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02859142 · ClinicalTrials.gov registry record · Phase 4
Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation
A Phase 4 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 122
- Enrollment target
NCT02859142: Completed Phase 4 study, sponsored by University of Chicago.
NCT02859142 is a Phase 4 study that has completed, run by University of Chicago. The registered enrollment target is 122 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02859142, a Phase 4 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 122 participants
- Enrollment target
Study Summary
The purpose of this study is to learn if the combination of a study drug and patch is more effective in helping heavy drinkers stop smoking than just the patch alone The study drug, varenicline, has been approved by the Food and Drug Administration (FDA) to help people stop smoking, but it is not known if the addition of varenicline to standard smoking cessation treatment with nicotine patches will help people stop smoking who are regular, frequent drinkers. This study is being done because cigarette smoking is the number one preventable cause of death and disease in the United States.
Primary Outcome
Number of participants reporting smoking abstinence at 12 weeks from baseline (smoking quit date) via subjective and biologically verified reports.
Interventions
- DRUG Placebo
- DRUG Chantix
- BEHAVIORAL Behavioral Counseling Sessions
- DRUG NicodermCQ
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2018-03-29 |
| Est. Completion | 2020-10-15 |
| Phase | Phase 4 |
What the finished NCT02859142 record still lists
NCT02859142 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02859142 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02859142 about?
NCT02859142 is a clinical study titled "Varenicline Augmentation of Patch Outcomes in Heavy Drinkers' Smoking Cessation". The purpose of this study is to learn if the combination of a study drug and patch is more effective in helping heavy drinkers stop smoking than just the patch alone The study drug, varenicline, has been approved by the Food and Drug Administration (FDA) to help people stop smoking, but it is not kn...
What is the current status of trial NCT02859142?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 122 participants. The study started on 2018-03-29. Estimated completion is 2020-10-15.
What interventions are being tested in trial NCT02859142?
The interventions under investigation include: Placebo (DRUG), Chantix (DRUG), Behavioral Counseling Sessions (BEHAVIORAL), NicodermCQ (DRUG).
Who is sponsoring clinical trial NCT02859142?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02859142's enrollment target sits among peer trials
122 665th of 2000 higher than 1,332 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI